Fig 1: Bioactivity-guided fractionation of macrophage lysate coupled to mass spectrometry (MS) identifies candidate filament-inducing proteins(A–C) A filament-inducing component in macrophage lysate is likely a phosphorylated protein. (A) Representative images of the HWP1p-GFP strain incubated for 6 h at 30°C with J774A.1 lysate that had been pre-treated with Proteinase K, phosphatase buffer alone as a control, or calf intestinal phosphatase. (B) Analysis of C. albicans cells in (A) by flow cytometry as described for Figure 1E. (C) Quantification of flow cytometry data in (B) as described for Figure 1F. Error bars indicate SD for technical triplicates, and statistical significance was calculated using a two-sided unpaired t test. ****p ≤ 0.0001. For (A)–(C), data are representative of two biological replicates (n = 2).(D) Fractionation of macrophage lysate by reverse-phase liquid chromatography identifies robust filament-inducing activity in the fractions eluted with 25% and 35% acetonitrile (ACN). Representative images of C. albicans strain SN95 incubated with J774A.1 lysate fractions for 6 h at 30°C. Fractions were scored for their filament-inducing activity on a scale from 0 to 3, where 0 signifies yeast, 1 signifies short filaments or pseudohyphae, 2 signifies a mixed population of yeast and filaments, and 3 signifies predominantly filaments. Filamentation score for each fraction is indicated in the top right corner of the corresponding image.(E) MS analysis of fractions identifies the greatest number of spectra corresponding to the immunomodulatory protein prothymosin alpha (PTMA) in the 35% ACN fraction. Spectral counts for seven proteins with the highest number of spectra in the fraction eluted with 35% ACN is shown.
Fig 2: Immunoneutralization of PTMA reduces the filament-inducing activity of macrophage lysate(A–C) Targeting of PTMA in macrophage lysate using an N-terminal anti-PTMA antiserum reduces the ability of lysate to induce filamentation. (A) Representative images of the HWP1p-GFP strain incubated with J774A.1 lysate for 6 h at 30°C. Lysate was pre-incubated overnight with an antiserum against the N terminus of PTMA or non-immune rabbit serum as control. (B) Analysis of C. albicans cells in (A) by flow cytometry as described for Figure 1E. (C) Quantification of flow cytometry data in (B) as described for Figure 1F.(D–F) Targeting of PTMA in macrophage lysate using an affinity-purified antibody to a C-terminal epitope in PTMA abolishes the ability of lysate to induce filamentation. (D) Representative images of C. albicans strain HWP1p-GFP incubated with lysate for 6 h at 30°C. J774A.1 lysate was pre-incubated overnight with a C-terminal anti-PTMA antibody or polyclonal rabbit IgG as control. (E) Analysis of C. albicans cells in (D) by flow cytometry as described for Figure 1E. (F) Quantification of flow cytometry data in (E) as described for Figure 1F. For (C) and (F), error bars indicate SD for technical triplicates, and statistical significance was calculated using a two-sided unpaired t test. ****p ≤ 0.0001. For (A)–(F), data are representative of three biologically independent experiments (n = 3).(G) Immunoneutralization of PTMA abolishes the ability of BMDM lysate to induce C. albicans filamentation. Representative images of C. albicans strain HWP1p-GFP incubated with BMDM lysate for 6 h at 30°C. J774A.1 lysate was pre-incubated overnight with a C-terminal anti-PTMA antibody or polyclonal rabbit IgG as control. Data are representative of two biological replicates (n = 2).Scale bars: 25 μm. See also Figures S1 and S3.
Supplier Page from Abcam for Recombinant Rat PTMA protein (His tag)